Sign in
4

Changes in Ownership

Roivant Sciences Ltd. Filed Acc 0001635088-26-000071

President & Immunovant CEO sold 200,000 shares at an average $33.16 ($6,631,268)

  • President & Immunovant CEO acquired 200,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Venker Eric · President & Immunovant CEO

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2026-06-24 Exercise or conversion : show line 1 in the form 10b5-1 +200,000 $3.85 $770,000 1,813,063 D
2026-06-24 Sale : show line 2 in the form 10b5-1 −153,766 $33.05 $5,081,966 1,659,297 D
2026-06-24 Sale : show line 3 in the form 10b5-1 −46,234 $33.51 $1,549,301 1,613,063 D
Open-market sales · 200,000 sh · avg $33.16 · $6,631,268

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-06-24 Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (Right to Buy) −200,000 4,244,834 D
Loading xslF345X06/wk-form4_1782512028.xml…